Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Receivables (2017 - 2025)

Catheter Precision (VTAK) has disclosed Receivables for 9 consecutive years, with $123000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 14.95% to $123000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $123000.0, a 14.95% increase, with the full-year FY2024 number at $70000.0, down 48.91% from a year prior.
  • Receivables was $123000.0 for Q3 2025 at Catheter Precision, up from $115000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $228000.0 in Q2 2021 to a low of $17000.0 in Q3 2021.
  • A 5-year average of $94500.0 and a median of $95000.0 in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: tumbled 96.42% in 2021, then soared 207.69% in 2023.
  • Catheter Precision's Receivables stood at $21000.0 in 2021, then grew by 23.81% to $26000.0 in 2022, then skyrocketed by 426.92% to $137000.0 in 2023, then crashed by 48.91% to $70000.0 in 2024, then surged by 75.71% to $123000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Receivables are $123000.0 (Q3 2025), $115000.0 (Q2 2025), and $85000.0 (Q1 2025).